Macrolide Safety During Pregnancy: What's The Verdict?

Macrolide antibiotics are commonly used to treat bacterial infections in pregnant women, particularly those with suspected penicillin allergies. However, concerns have been raised about their safety during pregnancy, with some studies suggesting a link between macrolide use and an increased risk of birth defects, specifically heart defects.

While the majority of studies have not found evidence of an association between macrolide use and an increased risk of malformations or other adverse pregnancy outcomes, a small number of studies have reported a small increased risk of overall malformations, cardiac malformations, and miscarriage.

Given the conflicting evidence, it is recommended that macrolides be used with caution during pregnancy and that alternative antibiotics be considered if possible. However, it is important to note that infection itself can pose risks to the unborn baby, and macrolides may be the best treatment option in certain cases.

Macrolides and the risk of miscarriage

Macrolides are a group of antibiotics used to treat common bacterial infections. They are often used as an alternative for patients with penicillin allergies. The antibiotics in this group include erythromycin, clarithromycin, azithromycin, spiramycin, and telithromycin.

Macrolides are widely used during pregnancy to treat infections such as chlamydia, gonorrhoea, and upper respiratory infections. They are also used in cases of beta-lactam allergies and premature rupture of membranes.

While macrolides are commonly used during pregnancy, there are conflicting findings regarding their safety. The available evidence relating to miscarriage risk following macrolide use during pregnancy is inconsistent, with some studies reporting increased risks. However, these findings may be influenced by methodological biases or confounding factors. Therefore, further research is needed to clarify the association between macrolide use and miscarriage risk.

In a study published in the British Medical Journal (BMJ) in 2020, researchers found an association between macrolide use during early pregnancy and an increased risk of major birth defects, specifically heart defects. This study suggested that macrolides should be used with caution during pregnancy, and if possible, alternative antibiotics should be prescribed until more research is available.

Another study, published in the BMJ in 2021, analysed data from over 100,000 children born in the UK between 1990 and 2016. The results indicated that macrolide use during the first trimester was associated with a higher risk of any malformation compared to penicillin use, with an adjusted risk ratio of 1.55 and a 95% confidence interval of 1.19 to 2.03. Specifically, there was an increased risk of cardiovascular malformations, with an adjusted risk ratio of 1.62 and a 95% confidence interval of 1.05 to 2.51.

However, it is important to note that these studies are observational, and a causal relationship between macrolide use and birth defects has not been established. As mentioned by Sarah Stock, a senior clinical lecturer, this type of study "can never definitively prove a drug causes birth defects."

Recommendations for Pregnant Women

The available data suggest that macrolide use during pregnancy may be associated with a small increased risk of malformations and miscarriage. Therefore, it is recommended that macrolides be reserved for situations where there are no suitable alternatives with adequate pregnancy safety data. If macrolides are the only treatment option, the risk of problems is considered low, and pregnant women should not stop taking the antibiotics without consulting their doctor.

To summarise, while macrolides are commonly used during pregnancy to treat bacterial infections, especially in patients with penicillin allergies, there are conflicting findings regarding their safety. Some studies suggest an increased risk of miscarriage and birth defects, but further research is needed to confirm these associations. Pregnant women should consult their healthcare providers before taking any medication and should not stop taking prescribed antibiotics without medical advice.

Macrolides and the risk of pyloric stenosis in the neonate

Macrolides are a class of drugs used to treat various bacterial infections, including pneumonia, sinusitis, pharyngitis, and tonsillitis. They are also used to treat sexually transmitted infections and are often administered to patients with penicillin allergies. Macrolides are widely used for a variety of bacterial infections in pregnancy, including chlamydia, gonorrhoea, and premature rupture of membranes.

There have been concerns and conflicting studies about the safety of macrolides during pregnancy, with some studies claiming an association between macrolides and cardiovascular malformations in infants. Exposure to macrolides in early infancy has also been associated with an increased risk of pyloric stenosis and intussusception.

A 2013 study investigated the fetal safety of macrolides by examining their association with pyloric stenosis in a large administrative database of drug dispensing and pregnancy outcomes in Southern Israel. The study found no association between macrolide exposure in the third trimester of pregnancy and pyloric stenosis or intussusception. However, due to the small number of observations, no multivariate logistic regression was performed.

Another study, published in the British Medical Journal in 2021, found an association between macrolide use during pregnancy and an increased risk of birth defects, specifically heart defects. However, this study did not specifically investigate pyloric stenosis.

A 2019 meta-analysis examined the association between perinatal exposure to macrolides and the development of infantile hypertrophic pyloric stenosis (IHPS). The analysis found a significant association between postnatal exposure to macrolides, particularly erythromycin, and IHPS. However, the evidence on the effects of prenatal exposure to macrolides was inconclusive.

Overall, while there is some evidence of an association between macrolide use and pyloric stenosis in neonates, particularly with postnatal exposure, the current research is limited and inconclusive. Further large-scale studies are needed to fully understand the potential risks associated with macrolide use during pregnancy and their impact on the development of pyloric stenosis in neonates.

Macrolides and the risk of cardiac malformations

Macrolides are a group of antibiotics that are commonly used to treat upper and lower respiratory infections and some sexually transmitted diseases. They have been linked to an increased risk of cardiac malformations and other adverse cardiac events when taken during pregnancy.

Several studies have found an association between macrolide use during pregnancy and an increased risk of birth defects, specifically heart defects, in children. A study published in the British Medical Journal (BMJ) in 2020 found that children born to mothers who were prescribed macrolides during early pregnancy had an increased risk of major birth defects, particularly heart defects, compared to children whose mothers received penicillin. Another study, published in the BMJ in 2013, found that macrolide use during the first trimester of pregnancy was associated with a higher risk of any malformation compared to penicillin use, with a specific increase in the risk of cardiovascular malformations. This study also found that erythromycin use in the first trimester was linked to a higher risk of any major malformation compared to penicillin.

The increased risk of cardiac malformations associated with macrolide use during pregnancy may be due to the ability of macrolides to block the delayed rectifier potassium channel, IKr, resulting in QT interval prolongation and torsades de pointes (TdP). This can lead to early afterdepolarizations of cardiac myocytes, which can induce TdP and result in fatal ventricular fibrillation. Additionally, there is evidence that macrolides can initiate an inflammatory cascade, leading to the formation of vulnerable plaques and an increased risk of acute coronary syndrome or sudden cardiac death.

However, it is important to note that the findings of these studies are observational, and more research is needed to establish a causal relationship between macrolide use during pregnancy and cardiac malformations. The benefits of macrolides in treating infections during pregnancy must also be considered when evaluating the risks.

Macrolides and the risk of genital malformations

Macrolides are a group of antibiotics that are commonly used to treat bacterial infections in pregnant women. However, macrolides also expose people to the risk of adverse events.

Macrolides are generally considered safe to use during pregnancy, but there are some concerns about their use. A study by Worm et al.(2021) found that macrolides were not associated with an increased risk of major birth defects. However, another study by Bahat Dinur et al. (2013) found that macrolides were associated with an increased risk of cardiovascular malformations.

Macrolides are generally considered safe to use during pregnancy, but it is important to weigh the benefits against the risks. It is recommended to consult with a healthcare provider before taking any medication during pregnancy.

Macrolides and the risk of musculoskeletal malformations

Macrolides are a group of antibiotics that are commonly used to treat bacterial infections. They are often used as an alternative for patients with a penicillin allergy. However, macrolides have been linked to an increased risk of birth defects in children when prescribed during pregnancy.

A study published in the British Medical Journal (BMJ) found that children born to mothers prescribed macrolide antibiotics during early pregnancy had an increased risk of major birth defects, specifically heart defects, when compared to children whose mothers received penicillin. This has led to concerns regarding the use of macrolides during pregnancy, with some countries avoiding prescribing macrolides to pregnant women.

Another study, published in the BMJ, found an association between macrolide use during pregnancy and an increased risk of any malformation, specifically cardiovascular malformations. This study also found an increased risk of genital malformations when macrolides were prescribed during any trimester.

Macrolides have also been associated with an increased risk of pyloric stenosis and intussusception in infants exposed to the antibiotics during very early infancy.

While the findings are observational and do not establish a causal relationship, they highlight the potential risks associated with macrolide use during pregnancy. It is important to consider alternative antibiotics for pregnant women when possible.

To address these uncertainties, further research is needed to analyze the association between macrolide antibiotics prescribed during pregnancy and major malformations, as well as neurodevelopmental disorders.

Frequently asked questions